drugset

drugset / Trial / NCT02500849

Safety Study of Zinc Finger Nuclease CCR5-modified Hematopoietic Stem/Progenitor Cells in HIV-1 Infected Patients

NCT02500849 ↗

Phase 1 Active not recruiting 12 enrolled City of Hope Medical Center California Institute for Regenerative Medicine (CIRM) · collab Sangamo Therapeutics · collab

Non-randomizedSingle-groupOpen-labelTreatment

Summary

The purpose of the study is to evaluate the safety and feasibility of administering SB-728mR-HSPC after conditioning with busulfan.

Timeline

Start: 2016-03-10
Primary completion: 2026-08-24
Completion: 2026-08-24

Publications

DiGiusto DL, Cannon PM, Holmes MC, Li L, Rao A, Wang J, Lee G, Gregory PD, Kim KA, Hayward SB, Meyer K, Exline C, Lopez E, Henley J, Gonzalez N, Bedell V, Stan R, Zaia JA. Preclinical development and qualification of ZFN-mediated CCR5 disruption in human hematopoietic stem/progenitor cells. Mol Ther Methods Clin Dev. 2016 Nov 9;3:16067. doi: 10.1038/mtm.2016.67. eCollection 2016.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Busulfan	Small molecule	—	—
Subject	SB-728mR-HSPC	Cell therapy	—	—

Indications